Vertaling van "approximately " (Nederlands → Frans) :

Approximately 90 million to 120 million doses are expected to be produced by the end of 2009, with expected fourthquarter net sales contributions of approximately USD 400 million to USD 700 million.
Il est prévu de produire entre environ 90 et 120 millions de doses d'ici fin 2009. Ce qui correspond à des contributions de l’ordre d’USD 400 à 700 millions environ au chiffre d’affaires net du quatrième trimestre.

Consumer Health – Gerber Business Unit On September 1, Novartis completed the divestment of the Gerber infant products Business Unit for approximately USD 5.5 billion to Nestlé S.A. resulting in a pre-tax divestment gain of approximately USD 4.0 billion and an after-tax gain of USD 3.6 billion.
Consumer Health – unité d’affaires Gerber Le 1 er septembre, Novartis a finalisé la cession de l’unité d’affaires Gerber alimentation pour bébés à Nestlé S.A. pour un montant d’environ USD 5,5 milliards. Il en est résulté un gain de cession avant impôts d’USD 4,0 milliards environ et un gain après impôts d’USD 3,6 milliards.

The transaction represents a total value of approximately Rs 3.7 billion (or approximately USD 78 million). Almost all large institutional investors and quasiinstitutional shareholders participated in the offer.
La transaction représente une valeur totale d’INR 3,7 milliards environ (approximativement USD 78 millions) Presque tous les grands investisseurs institutionnels et les actionnaires quasi-institutionnels y ont participé.

The preliminary estimate of the additional pre-tax amortization of intangible assets is approximately USD 2.1 billion per year, with an estimated expense for the four months of 2010 of approximately USD 400 million including the required amortization of inventory revalued to its estimated fair value.
L’estimation préliminaire de l’amortissement supplémentaire avant impôts des immobilisations incorporelles se chiffre à USD 2,1 milliard environ par an, et à une charge estimée à USD 400 millions environ pour les quatre derniers mois de 2010, y compris l’amortissement des stocks réévalués à leur juste valeur estimée.

Vaccines and Diagnostics: USD 543 million (–18%, –16% lc) Approximately 27 million doses of seasonal flu vaccines were delivered for the 2009/2010 season in the US and Europe by early October 2009, with net sales per dose down slightly from the 2008 period due mainly to price pressure in the US.
Vaccins et Diagnostic: USD 543 millions (-18%, -16% en m. l). Début octobre 2009, quelque 27 millions de doses de vaccins contre la grippe saisonnière ont été livrées pour la saison 2009/2010 aux Etats-Unis et en Europe.

Net sales of approximately USD 17 million were recorded in the 2009 quarter for H1N1 pandemic flu vaccines delivered in late September.
Un chiffre d’affaires net d’USD 17 millions environ a été enregistré au troisième trimestre 2009 pour les vaccins contre la pandémie grippale H1N1 fournis à fin septembre.

At European level, important texts were adopted such as Directive 2007/47/EC amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, and Regulation (EC) no. 1394/2007 on advanced therapy medicinal products.
At European level, important texts were adopted such as Directive 2007/47/EC amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, and Regulation (EC) no. 1394/2007 on advanced therapy medicinal products.

In 2007, the number of applications submitted in MeSeA on a weekly basis rose by approximately 30%.
In 2007, the number of applications submitted in MeSeA on a weekly basis rose by approximately 30%.

Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.
Each report of an adverse effect is now processed in two phases. For the first phase “preparing” the electronic report approximately 60 % of the backlog has been removed.

Diovan (USD 4.4 billion, +5% lc) achieved solid worldwide growth, driven by expansion in Japan, which accounts for approximately 20% of net sales and where the Co-Dio diuretic combination therapy was launched in 2009.
Diovan (USD 4,4 milliards, +5% en m. l) a enregistré une solide croissance mondiale, emmenée par l’expansion au Japon, qui compte pour environ 20% du chiffre d’affaires net, et où Co-Dio, un traitement associé à un diurétique, a été lancé en 2009.